AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

Core Insights - AbbVie and Gilgamesh Pharmaceuticals have entered into a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders, focusing on neuroplastogens that aim to improve treatment outcomes for mental health issues [1][2] - The collaboration seeks to leverage AbbVie's expertise in psychiatry and Gilgamesh's innovative research platform to discover novel compounds that minimize the psychoactive effects associated with first-generation psychedelic treatments [1][2] - The agreement includes an upfront payment of $65 million to Gilgamesh, with potential total payments reaching up to $1.95 billion, alongside tiered royalties on net sales [2] Company Overview - AbbVie is committed to discovering and delivering innovative medicines across key therapeutic areas, including neuroscience, with a focus on addressing serious health issues [3] - Gilgamesh Pharmaceuticals is a clinical-stage biotech company developing new chemical entities that target the root causes of psychiatric diseases, moving towards rapid-acting and durable therapies [4]